Novo Nordisk reports positive weekly growth hormone data
![Photo: Novo Nordisk / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14139195.ece/ALTERNATES/schema-16_9/doc7lex5hsehs61kp3oqbm1.jpg)
Novo Nordisk has presented positive results from a phase III trial of its treatment for children with growth hormone deficiency, dubbed Sogroya, according to a company press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
General Manager of Novo Nordisk in Denmark to move to Japan
For subscribers
FDA rejects Pfizer's weekly growth hormone
For subscribers